Brief Communication | Published:

Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

Nature Genetics volume 45, pages 131132 (2013) | Download Citation


Solitary fibrous tumors (SFTs) are rare mesenchymal tumors. Here, we describe the identification of a NAB2-STAT6 fusion from whole-exome sequencing of 17 SFTs. Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors (55%), representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Semin. Oncol. 36, 312–323 (2009).

  2. 2.

    et al. Mol. Cell. Biol. 16, 3545–3553 (1996).

  3. 3.

    et al. PLoS ONE 4, e7620 (2009).

  4. 4.

    et al. Am. J. Pathol. 177, 70–83 (2010).

  5. 5.

    et al. Hum. Pathol. 32, 935–939 (2001).

  6. 6.

    , , & BMC Bioinformatics 8, 5 (2007).

  7. 7.

    , , & Cytokine Growth Factor Rev. 17, 173–188 (2006).

  8. 8.

    , , & Oncotarget. 2, 518–524 (2011).

  9. 9.

    , , , & BMC Cancer 11, 184 (2011).

  10. 10.

    et al. J. Biol. Chem. 281, 31369–31379 (2006).

  11. 11.

    et al. Cell 150, 1107–1120 (2012).

  12. 12.

    et al. Nature 489, 519–525 (2012).

  13. 13.

    et al. Nat. Genet. 44, 685–689 (2012).

  14. 14.

    et al. Nature 488, 106–110 (2012).

  15. 15.

    et al. Nature 486, 405–409 (2012).

Download references


We are grateful to the individuals with SFT who contributed material for this study. We thank members of the Genomics Platform at the Broad Institute for their technical expertise and M. Abazeed and A. Dulak for critically reviewing the manuscript. This work was conducted as part of the Slim Initiative for Genomic Medicine in the Americas (SIGMA), a project funded by the Carlos Slim Health Institute in Mexico. This work was supported by a Specialized Program of Research Excellence (SPORE) grant in Soft Tissue Sarcoma (P50 CA140146) and a P01 grant (P01CA47179) to S. Singer (MSKCC). J.C. is supported by an American Cancer Society AstraZeneca Postdoctoral Fellowship. A.M.C. is supported by a grant from the Kristen Ann Carr Foundation. M.M. is supported by generous donations from M.B. Zuckerman and Team Dragonfly of the Pan-Mass Challenge. Material was collected under institutional review board (IRB)-approved protocols at the Memorial Sloan-Kettering Cancer Center and the Oregon Health & Science University Biolibrary. All patients provided informed consent.

Author information

Author notes

    • Juliann Chmielecki
    •  & Aimee M Crago

    These authors contributed equally to this work.


  1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

    • Juliann Chmielecki
    • , Sarah R Walker
    • , David A Frank
    •  & Matthew Meyerson
  2. Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.

    • Juliann Chmielecki
    • , Mara Rosenberg
    • , Lauren Ambrogio
    • , Daniel Auclair
    • , Aaron McKenna
    •  & Matthew Meyerson
  3. Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

    • Aimee M Crago
    •  & Rachael O'Connor
  4. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

    • Sarah R Walker
    •  & David A Frank
  5. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

    • Sarah R Walker
    •  & David A Frank
  6. Division of Hematology and Medical Oncology, Portland Veterans Affairs (VA) Medical Center and the Oregon Health & Science University (OHSU) Knight Cancer Institute, Portland, Oregon, USA.

    • Michael C Heinrich
  7. Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.

    • Matthew Meyerson


  1. Search for Juliann Chmielecki in:

  2. Search for Aimee M Crago in:

  3. Search for Mara Rosenberg in:

  4. Search for Rachael O'Connor in:

  5. Search for Sarah R Walker in:

  6. Search for Lauren Ambrogio in:

  7. Search for Daniel Auclair in:

  8. Search for Aaron McKenna in:

  9. Search for Michael C Heinrich in:

  10. Search for David A Frank in:

  11. Search for Matthew Meyerson in:


J.C. and M.M. conceived the project. J.C., A.M.C. and M.M. wrote the manuscript with input from all coauthors. J.C., A.M.C. and R.O. performed experiments. J.C. and M.R. performed computational analyses. A.M. contributed an unpublished algorithm to the analysis. J.C., A.M.C., M.R., S.R.W., R.O., D.A.F. and M.M. analyzed the results. A.M.C. and M.C.H. contributed samples. L.A. and D.A. facilitated the transfer, sequencing and analysis of samples.

Competing interests

M.M. is a paid consultant for and equity holder in Foundation Medicine, a genomics-based oncology diagnostics company, and is a paid consultant for Novartis. M.C.H. is a paid consultant for and equity holder in Molecular MD, a molecular diagnostics company, and is a paid consultant for Novartis.

Corresponding author

Correspondence to Matthew Meyerson.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Methods, Supplementary Figures 1–4 and Supplementary Tables 1–5

About this article

Publication history





Further reading